AveXis Sale: An $8.7 Billion Endorsement for Gene Therapy – Barron’s
Barron’s |
AveXis Sale: An $8.7 Billion Endorsement for Gene Therapy
Barron’s Review | Preview. Last Monday may have been validation day for replacement gene therapy—a promising biotechnology treatment for some diseases that substitutes healthy genes for diseased ones. That day, AveXis (ticker: AVXS), a leader in the field … |
